Fantasy baseball analyst Fred Zinkie shares his safest picks by round in a 10-team draft. With Fernando Mendoza all but a ...

New research reveals a surprising threat to brain health—one that many active people may be overlooking.

Stifel 2026 Virtual CNS Forum March 17, 2026 2:00 PM EDTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...

Evoke and Evoke+ -- the randomized, double-blind, placebo-controlled phase 3 trials conducted across 566 sites in 40 countries -- showed that semaglutide led to no significant difference after two ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for cognition or function in patients with early Alzheimer’s.

Explore Eli Lilly and Company stock: obesity drug tirzepatide sales +115%, new retatrutide diabetes data, and Kisunla ...

At Georgia Tech, we turn deep science into therapies that could give people back what matters most. Memory isn't just stored in the brain. It's woven into who we are. Georgia Tech researchers explain ...

New findings suggest that targeting inflammation in Alzheimer’s may matter as much as targeting protein buildup.

Researchers say they have developed a blood test that can help predict the start of Alzheimer's disease symptoms, allowing them to receive a diagnosis.

Alzheimers disease is diagnosed by measuring amyloid plaques and tau tangles, formed due to accumulation of amyloid and tau proteins in ones brain ...

In TODAY.com's Expert Tip of The Day, a neurologist explains how playing games that build cognitive speed can protect against ...